Viral oncolysis for malignant liver tumors.
Viral oncolysis represents a unique strategy to exploit the natural process of viral replication to kill tumor cells. Although this concept dates back nearly a century, recent advances in the fields of molecular biology and virology have enabled investigators to genetically engineer viruses with greater potency and tumor specificity. In this article we review the general mechanisms by which oncolytic viruses achieve their antineoplastic efficacy and specificity. We focus on the development of several classes of oncolytic viruses for the treatment of malignant liver tumors, including adenoviruses, vaccinia viruses, and herpes simplex viruses, and discuss the results of clinical trials for these viruses. We also describe results from our laboratory research program, which is focused on developing effective, liver tumor-specific Herpes simplex virus 1 mutants.
Mullen
John T
JT
Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Tanabe
Kenneth K
KK
D000256:Adenoviridae / Q000235:genetics / Q000472:pathogenicity*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005818:Genetic Engineering; D015316:Genetic Therapy; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000472:pathogenicity*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy* / Q000821:virology*; D014616:Vaccinia virus / Q000235:genetics / Q000472:pathogenicity*; D014779:Virus Replication